ROS1 and non-small cell lung carcinoma: In ROS1-positive NSCLC patients, treatment with the ROS1 inhibitor crizotinib led to progression-free survival (PFS) of around 8.5 months for individuals with p53 gene mutations, whereas those with a wild-type p53 gene had a longer PFS of approximately 15.5 months [63].